Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Probucol is a lipid-lowering agent and powerful antioxidant originally developed to prevent the degradation of rubber, later repurposed for medical use to reduce serum low-density lipoprotein cholesterol (LDL-C) levels. It lowers cholesterol by increasing the rate of LDL catabolism and enhancing excretion into bile, independent of the LDL receptor. Probucol also inhibits ABCA1-mediated cellular lipid efflux, which reduces HDL cholesterol (HDL-C) by about 30%, but increases reverse cholesterol transport capacity overall. Its antioxidant properties help prevent oxidation of LDL particles, potentially slowing atherogenesis. The drug was withdrawn from several Western markets due to safety concerns, including QT prolongation[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on probucol.